目的:探討益生菌聯合營養支持對胃腸外科術后患者腸功能和腸道菌群的影響。方法:36例胃腸道中等以上手術的患者,隨機分為研究組和對照組,每組18例。兩組術后均接受等氮等能量的營養支持,研究組患者于術后第3天開始每天加用益生菌制劑(6.6 × 10.7 colony forming units),共7天。監測治療期間患者的胃腸道癥狀、生命體征、腹瀉情況和菌群比例等。結果:兩組患者術后腹痛、腹脹、腸鳴音異常等胃腸道癥狀均無顯著差異 (Pgt;0.05),兩組患者在術后第8和9天的腹瀉比例和腹瀉評分差異有顯著性意義(Plt;0.05)。治療結束后,研究組患者腸道雙歧桿菌和乳酸桿菌計數均較對照組高,兩組間差異有顯著性意義(Plt;0.05)。 結論:在胃腸外科術后患者中應用益生菌可改善胃腸道癥狀、減輕腹瀉程度和糾正腸道菌群失調。
This study aims to compare the prostate cancer detection rate between magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) cognitive fusion targeted biopsy and systematic biopsy. A total of 614 patients who underwent transrectal prostate biopsy during 2016-2018 with multiparametric magnetic resonance imaging (mpMRI) were included. All patients with a PI-RADS V2 score ≥ 3 accepted both targeted biopsy and systematic biopsy, and those with a PI-RADS V2 score ≤ 2 only accepted systematic biopsy. Overall prostate cancer detection rate between the two biopsies was compared. MRI-TRUS cognitive fusion targeted biopsy identified 342 cases (75.7%) of prostate cancer while systematic biopsy identified 358 cases (79.2%). There was no significant difference in the detection rate between the two groups (χ2 = 1.621, P = 0.203). Targeted biopsy had significant fewer biopsy cores compared with systematic biopsy, reducing (9.3 ± 0.11) cores (P < 0.001) in average. Targeted biopsy had about 10.8% (P < 0.001) more tumor tissues in positive cores compared with systematic biopsy. The results show that both MRI-TRUS cognitive fusion targeted biopsy and systematic biopsy have good detection rate on prostate cancer. Cognitive targeted biopsy may reduce biopsy cores and provide more tumor tissues in positive cores.